ApeldoornSYVischjagerMKathalijnJ, et al. (2022) The antidepressant effect and safety of non-intranasal esketamine: A systematic review. Journal of Psychopharmacology36: 529–542.
2.
ChristensenMCSchmidtSGrandeI, et al. (2022) Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study. Journal of Psychopharmacology36: 564–575.
3.
CostaTMenzatBEngelthalerT, et al. (2022) The burden associated with, and management of, difficult-to-treat depression in patients under specialist psychiatric care in the UK. Journal of Psychopharmacology36: 543–554.
4.
DijkstraFvan de LooAAbdulahadS, et al. (2022) The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder. Journal of Psychopharmacology36: 612–623.
5.
EspinolaCKhooY, et al. (2022) Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BINDssss-1 study report. Journal of Psychopharmacology36: 602–611.
6.
FisherPMOzenneBGanzM, et al. (2022) Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response – A NeuroPharm Study. Journal of Psychopharmacology36: 624–634.
7.
GeorgeSMaitiRMishraA, et al. (2022) Efficacy and safety of supraphysiologic doses of levothyroxine for patients with bipolar depression in adults: A systematic review. Journal of Psychopharmacology36: 519–528.
8.
ItsukiTHonyashikiMInoueT (2022) A Letter to the Editor, associated with the article entitled “Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium” by Vázquez et al. (Journal of Psychopharmacology, 2021, Vol. 35(8) 890–900). Journal of Psychopharmacology36: 651–652.
9.
McKeownLTaylorRWDayE, et al. (2022) Patient perspectives of lithium and quetiapine augmentation treatment in treatment resistant depression: A qualitative assessment. Journal of Psychopharmacology36: 555–563.
10.
SchulkensJDeckersKJenniskensM, et al. (2022) The effects of selective serotonin reuptake inhibitors on memory functioning in older adults: A systematic literature review. Journal of Psychopharmacology36: 576–591.
11.
van SlotenTTSouvereinPCCStehouwerCDA, et al. (2022) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and risk of depression among older people with hypertension. Journal of Psychopharmacology36: 592–601.
12.
WozniakJDiSalvoMFarrellA, et al. (2022) Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, aripiprazole, ziprasidone, and quetiapine. Journal of Psychopharmacology36: 635–642.
13.
ZouYGrigorianAKarthikeyanS, et al. (2022) Elevated C-reactive protein among symptomatic youth with bipolar disorder. Journal of Psychopharmacology36: 643–650.
